Drug Profile
Azintuxizumab vedotin - AbbVie
Alternative Names: ABBV-838Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action CD319 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in France (Parenteral)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Germany (Parenteral)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Spain (Parenteral)